StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
THRL.L$107.40-1.65%
Fair $107.40+0.0%

THRL.L

Target Healthcare REIT Ord

Unknown / UnknownLSE

$107.40

-1.80 (-1.65%)

Fairly Valued+0.0%Fair Value $107.40Fund rank 32/100 · Data gapFallback financials|
SA 44/C
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $30.4M · quality 46.0/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 52/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

44/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific NAV/AFFO model required: REIT/real-estate targets are disabled until FFO/AFFO/NAV/cap-rate data exists. REIT NAV/AFFO valuation requires positive AFFO/share history or TTM AFFO/share; generic FCF remains disabled.
Thesis & Journal · THRL.LLocal privado en este navegador · Target Healthcare REIT Ord
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$666M

P/E

8.3x

↓

EV/EBITDA

N/A

•

ROE

10.6%

↑

Gross Margin

N/A

•

Debt/Equity

0.35

↑
52-Week Range$107
$92$111

TradingView lightweight chart

THRL.L price, volumen y niveles de valoración

Último $107.40Periodo +4.8%
Fair value: $107.40

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2024 · 3 años de histórico normalizado

Revenue CAGR

+15.7%

FCF CAGR

+19.3%

FCF margin

54.0%

FCF / Net income

0.58x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $78.5M · net income $73.0M · FCF $42.3M

2021-FY → 2024-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

93.0%+6.5% pts

FCF margin

54.0%+4.7% pts
MetricTTM
2024
2023
2022
2021
Income Statement
Revenue$78.5M$78.5M$-1.9M$56.1M$50.7M
Net Income$73.0M$73.0M$-6.6M$49.1M$43.9M
EPS0.120.12-0.010.080.09
Net Margin93.0%93.0%338.6%87.6%86.6%
Balance Sheet
Debt/Equity0.350.350.350.330.23
Cash Flow
Free Cash Flow$42.3M$42.3M$29.7M$30.4M$25.0M
Returns
ROE10.6%10.6%-1.0%7.0%7.8%
Valuation
P/E8.268.26—1353.661267.61
P/B96.6496.6467.7395.1798.41
Growth & Yield
Revenue Growth4143.3%4143.3%-103.5%10.6%—
EPS Growth1210.4%1210.4%-112.9%-11.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

332.6%

muy exigente

EPS terminal req.

$9.53

Spread vs growth

877.8%

5Y implied EPS CAGR

150.2%

muy exigente

EPS terminal req.

$11.53

Spread vs growth

1060.2%

10Y implied EPS CAGR

65.9%

muy exigente

EPS terminal req.

$18.57

Spread vs growth

1144.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +7.9%

Total return

+7.9%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.01 → 0.12

Residual

+7.9%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+7.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.